Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05351554 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
A Phase 2 study, sponsored by Kinevant Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05351554 is a Phase 2 study that was terminated before completion, run by Kinevant Sciences. The registered enrollment target is 1 participants.
The verdict
NCT05351554, a Phase 2 study, was terminated before completion, sponsored by Kinevant Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.
Interventions
- DRUG Namilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-08-23 |
| Est. Completion | 2022-12-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05351554
The ClinicalTrials.gov registry entry for NCT05351554 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kinevant Sciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Namilumab is the first listed.
NCT05351554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05351554 about?
NCT05351554 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis". A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.
What is the current status of trial NCT05351554?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-08-23. Estimated completion is 2022-12-13.
What interventions are being tested in trial NCT05351554?
The interventions under investigation include: Namilumab (DRUG).
Who is sponsoring clinical trial NCT05351554?
This trial is sponsored by Kinevant Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.